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ABSTRACT 
This paper divides working capital into working capital of operating activities and working capital of financing activities. 
Working capital of operating activities can be further divided into working capital of procurement channels, working capital of 
productive channels and working capital of marketing channels by channel. Then we analyze the data in the balance sheet and 
income statement from Shenzhen biological, pharmaceutical listed companies in 2012 by the statistical description. Finally, we 
study the status of its working capital management. 
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INTRODUCTION                                                                     
he global economy stays in a period of adjustment 
after the crisis in 2012.Although the domestic 
economy has already become steady the new 
balance has not been built. There are still many 
problems, such as growing cost of raw material and 
overcapacity, to be solved. Meanwhile, the growing 
popularity of the health insurance and the increasing 
national investments in health care can easily boost the 
expansion of pharmaceutical industry market. 
Accordingly, the competition in pharmaceutical industry 
is converting gradually from product to brand and the 
new GMP standard brings opportunities as well as 
challenges. As a consequence, bio-pharmaceutical 
industry has encouraged companies to focus on 
competitive enterprise and promote industrial upgrade, 
and as a high technology enterprise, bio-pharmaceutical 
industry shows high investments, high risks and high 
returns and enterprises always sexert a lot of effort to 
exploit new drugs. 
Professor Zhuquan Wang was the first to propose 
working capital management on the basis of channel and 
to advocate integrating it with Supply Chain 
Management, Channel Management and Customer 
Relationship Management. He divided working capital 
into working capital of operating activities and working 
capital of financing activities, and further divided 
working capital of operating activities into working 
capital of procurement channels, working capital of 
productive channels and working capital of marketing 
channels. He has improved the traditional methods of 
working capital, and has brought new ideas into working 
capital management. 
 
SAMPLE DATA AND SURVEY SYSTEM 
The selection of the sample 
We study a listed company in Shenzhen bio-
pharmaceutical as objects. The data is obtained from 
CNNIC, a leading professional organization in china. 
There are two main principles to follow in order to choose 
objects: 1. Data integrity and the relevant parameters can 
be calculated.2. For statistical analysis; there is a need to 
exclude the abnormal data or newly listed data in 2012. 
Finally we select 46 listed bio-pharmaceutical companies 
as objects of study, according to the principles above. 
 
Indicators selected 
Stocks in procurement channels: raw materials, key 
materials, packaging materials, fuel, auxiliary materials, 
purchased semi-finished products (purchased parts), and 
repair parts (spare parts). 
Stocks inproductive channels: work in progress, semi-
finished goods, consumptive biological assets, revolving 
materials, work in process outsourced, cost of 
development, and low-value consumption goods. 
Stocks in marketing channels: finished goods, goods in 
transit, and inventory of goods. 
Other stocks in small amount are not specifically classified. 
50% of the other stocks figure in procurement channels, and 
the remains figure in the productive channels. 
Specific index calculation formula: 
Turnover days of working capital of marketing channel = 
Working capital of marketing channel ÷ (Operating 
income/360) = ( Finished goods+ Account receivable+ 
Notes receivable- Deposit Received- Tax payable) ÷
(Operating income/360) 
T 
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Turnover days of working capital of productive channels 
= Working capital of productive channels÷(Operating 
income/360) = ( Work in progress+ Semi-finished goods+ 
Other receivables+ Deferred and prepaid expenses-
Employee pay payable- Other payables- Accrued 
Expenses) ÷(Operating income/360). 
Turnover days of working capital of procurement 
channels = Working capital of Procurement channels÷
(Operating income/360) = (Material inventory+ Advance 
money-Accounts Payable-Notes payable)÷ (Operating 
income/360). 
Turnover days of working capital of financing activities = 
Working capital of Financing activities ÷ (Operating 
income/360) = (Cash and cash equivalents+ Interest 
receivable+ Dividend receivable+ Transaction monetary 
assets and so on- Short-term loans- Accrued interest payable-
Dividends Payable) ÷(Operating income/360). 
Income is derived from the annual income statement of 
"Operating income". Finished goods, notes receivable, 
deposit received, tax payable, other receivables, deferred, 
prepaid expenses, employee pay payable and so on are the 
mean of beginning balance and ending balance from the 
balanced sheet. And account receivable, other receivables 
and stock are the mount which indicates the net worth after 
deducting depreciation preparation in balanced sheet. 
 
Data sources 
As needed, the paper includes data: the beginning balance 
and ending balance of mobility projects from the annual 
balance sheet of bio-pharmaceutical listed companies(such as 
cash and cash equivalents, account receivable, notes 
receivable, advance money, other receivables, stock, short-
term loans, deposit received, notes payable, other payables 
and so on), operating income items from annual income 
statement of bio-pharmaceutical listed companies and the 
specific items of stock from balance sheet of bio-
pharmaceutical listed companies. This report forms through 
statistical data without modifying anything. 
 
Analytical method 
Through statistical methods, we use excel to analyze the 
management performance of working capital in Shenzhen 
bio-pharmaceutical listed companies. At first, we figure out 
the average of working capital in every Shenzhen bio-
pharmaceutical listed companies. Then we analyze the 
management situation of the companies according to the data 
and find out the problems of management of working capital 
in Shenzhen bio-pharmaceutical listed companies. 
 
THE ANALYSIS OF WORKING CAPITAL MANAGEMENT 
IN SHENZHEN BIO-PHARMACEUTICAL LISTED 
COMPANIES IN 2012 
Through statistical methods, we can figure out that the 
average of turnover days of working capital of marketing 
channel is 136.64 days. Among the 46 companies, there are 
15 companies whose turnover days of working capital of 
marketing channel amount to or less than 100 days,6 
companies whose turnover days of working capital of 
marketing channel are up to 200 days and one company 
whose turnover days of working capital of marketing 
channel turns out to be a minus. 
The average of turnover days of working capital of 
productive channel is 35.22 days. Among the 46 
companies, there are 6 companies whose turnover days of 
working capital of productive channel are more than 50 
days, 3 companies whose turnover days of working 
capital of productive channel are between -60 to -50 in 
total and 17 companies whose turnover days of working 
capital of productive channel turn out to be a minus. 
The average of turnover days of working capital of 
procurement channels is 85.93 days. Among the 46 
companies, there are 8 companies whose turnover days of 
working capital of procurement channels are more than 50 
days, 6 companies whose turnover days of working capital 
of procurement channels is less than -50days and 23 
companies whose turnover days of working capital of 
procurement channels turn out to be a minus. 
The average of turnover days of working capital of 
financing activities is 57.97days. Among the 46 
companies, there are 27 companies whose turnover days 
of working capital of financing activities are more than 50 
days, 5 companies whose turnover days of working 
capital of financing activities are less than -50days and 11 
companies whose turnover days of working capital of 
financing activities turn out to be a minus. 
We can infer that there is a huge difference in making use 
of working capital among Shenzhen biological, 
pharmaceutical listed companies, and the average of 
turnover days of working capital of marketing channel is 
relatively higher than the others. The reasons may lie: 
1.There is a huge number of finished goods stocking in the 
company which occupy a huge amount of money.2.There 
are plenty amount of account receivable we just cannot 
easily get it back. Excessive turnover days of working 
capital of marketing channel would reduce effective 
utilization of funds and bring down the yields, and the 
surplus of finished goods would undermine enterprises’ 
anti-risk capability. 
According to statistics, there are one company whose 
turnover days of working capital of marketing channel 
turns out to be a negative, 17 companies whose turnover 
days of working capital of productive channel turn out to 
be a negative, 23 companies whose turnover days of 
working capital of procurement channels turn out to be a 
negative and 11 companies whose turnover days of 
working capital of financing activities turn out to be a 
negative. With so many minus, we know it implies the 
instability in the use of the capital. If a company suffers 
from a sustaining shortage of capital, it can easily lead to 
the breakdown of the capital chain in the aspects of its 
productive, procurement or financial management. 
What’s more there is still a potential hazard left behind. 
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Table 1: Descriptive statistics 
The name of the company 
Turnover days of working capital of 
operating Activities 
Turnover days of 
working capital of 






PKU HEALTHCARE 146.39 -23.97 -118.70 -8.51 
NORTHEAST PHARM 136.45 14.34 -34.58 -125.18 
LANZHOU FOCI PHARMACEUTICAL CO.,LTD 180．23 21.08 55.35 245.01 
HANSEN PHARM 88.30 -22.85 18.14 486.63 
HUAPONT-NUTRICHEM CO.,LTD 97.83 -1.59 -54.63 -20.83 
CHINA RESOURCES SANJIU 
MEDICAL&PHARMACEUTICALCO,.LTD 
96.22 -56.34 -20.13 300.38 
HUASUN 161.70 0.84 -67.41 44.81 
JINLING PHARMACEUTICAL CO.,LTD 111.39 -17.39 -15.92 150.27 
JIU ZHI TANG 125.01 -56.97 -4.89 234.53 
QINGHAI GELATIN COMPANY LIMILED 141.54 8.36 16.44 13.57 
RENHE PHARMACY CO.,LTD 80.79 -5.17 -13.02 62.38 
TONGHUA GOLDEN-HOURSE GROUP 403.04 602.36 84.81 20.25 
ZHEJIANG NHU COMPANY LTD 106.60 53.91 -21.90 215.43 
SHANDONG XINHUA PHARMACEUTICAL CO.,LTD 9.20 -13.45 -37.92 -16.08 
ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL 
CO.,LTD 
146.58 4.52 -9.59 -205.12 
XIN BANG 198.71 97.38 72.20 187.49 
YUNNAN BAIYAO 109.08 8.16 -28.35 37.55 
ZHONGSHENG PHARMACY 104.30 -17.66 20.67 365.94 
BBCA PHARMACEUTICAL 87.57 -0.35 -20.68 -45.05 
DEEJ -1.90 -18.92 9.29 356.27 
LIVZON 79.14 -38.86 3.00 52.59 
HAIYAO 140.90 55.10 20.90 127.32 
UNISPLENDOUR GUHAN GROUP CORPORATION 
LIMITED 
200.78 7.13 -45.17 61.01 
JI LIN AODONG  97.14 -22.25 17.50 271.98 
APELOA 88.62 3.14 -98.75 -46.19 
GUANGJI PHARM 220.33 -67.31 -150.83 -111.72 
ZHEJIANG JINGXIN PHARMACEUTICAL CO.,LTD 68.52 8.75 -38.68 44.93 
HISOAR PHARMACEUTICAL 111.51 29.12 -34.90 -19.63 
WOHUA PHARMACEUTICALS 158.59 18.32 5.98 498.89 
JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL CO.,LTD 474.66 307.16 164.13 -604.77 
LAYN 126.70 526.27 -101.71 -342.51 
JIAYING PHARMACEUTICAL 122.41 19.55 17.78 29.89 
HENGKANG MEDICAL GROUP 106.90 28.36 41.80 143.80 
EHWA 81.53 0.52 -40.76 17.16 
SANJIN 99.66 -12.08 -16.69 19.92 
QIZHENG 162.81 0.18 40.77 199.95 
NT JHZY 146.32 -9.36 -20.34 149.20 
YATAI 206.52 20.19 -45.06 316.05 
TIJINLISHENG PHARMACEUTICA CO.,LTD 106.00 14.20 6.14 541.71 
HEPALINK 75.04 58.67 50.40 1374.41 
KL INDUSTRY GROUP 183.28 2.05 5.72 97.18 
GUIZHOU BAILING 255.11 33.00 21.90 78.47 
TAIANTANG 129.97 -10.90 188.37 202.38 
GLORIA PHARMACEUTICALS 15.48 22.23 127.11 711.49 
YISHENG-PHARMACEACEUTICA 193.47 22.57 43.50 531.94 
SHIJIAZHUANG YILING PHARMACEUTICAL CO.,LTD 104.59 28.28 102.54 354.94 
 
CONCLUSION 
Turnover days of working capital are a comprehensive 
indicator, and exploring working capital through the 
channel helps enterprise realize its shortage in the aspects of 
productive, procurement and marketing channel and find 
ways to improve it. Also there are some places we need to 
improve: First of all, the extent is limited to the year 2012, 
and it doesn’t rule out non-routine inputs or outputs which 
perhaps could impact the validity of the result. Secondly, the 
research doesn’t fully eliminate the irrelevant factors that 
may affect the conclusion to some extent. Thirdly, we regard 
biological, pharmaceutical listed companies as objects of 
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study, although it is particular, but it is not easy to compare 
in a single industry. 
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